Literature DB >> 24756547

The ALPPS approach: should we sacrifice basic therapeutic rules in the name of innovation?

J Figueras1, J Belghiti.   

Abstract

Mesh：

Year:  2014        PMID： 24756547     DOI： 10.1007/s00268-014-2540-0

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  5 in total

1.  Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.

Authors:  Andreas A Schnitzbauer; Sven A Lang; Holger Goessmann; Silvio Nadalin; Janine Baumgart; Stefan A Farkas; Stefan Fichtner-Feigl; Thomas Lorf; Armin Goralcyk; Rüdiger Hörbelt; Alexander Kroemer; Martin Loss; Petra Rümmele; Marcus N Scherer; Winfried Padberg; Alfred Königsrainer; Hauke Lang; Aiman Obed; Hans J Schlitt
Journal:  Ann Surg       Date:  2012-03       Impact factor: 12.969

2.  ALPPS for patients with colorectal liver metastases: effective liver hypertrophy, but early tumor recurrence.

Authors:  Karl J Oldhafer; Marcello Donati; Robert M Jenner; Axel Stang; Gregor A Stavrou
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

3.  Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases.

Authors:  François Cauchy; Béatrice Aussilhou; Safi Dokmak; David Fuks; Sébastien Gaujoux; Olivier Farges; Sandrine Faivre; Daniel Lepillé; Jacques Belghiti
Journal:  Ann Surg       Date:  2012-11       Impact factor: 12.969

4.  ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis.

Authors:  Erik Schadde; Victoria Ardiles; Ksenija Slankamenac; Christoph Tschuor; Gregory Sergeant; Nadja Amacker; Janine Baumgart; Kris Croome; Roberto Hernandez-Alejandro; Hauke Lang; Eduardo de Santibaňes; Pierre-Alain Clavien
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

5.  The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion.

Authors:  Giovanni Vennarecci; Andrea Laurenzi; Roberto Santoro; Marco Colasanti; Pasquale Lepiane; Giuseppe Maria Ettorre
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352
  5 in total
  5 in total

1.  The many faces of ALPPS: surgical indications and techniques among surgeons collaborating in the international registry.

Authors:  Suzana Buac; Erik Schadde; Andreas A Schnitzbauer; Kelly Vogt; Roberto Hernandez-Alejandro
Journal:  HPB (Oxford)       Date:  2016-03-10       Impact factor: 3.647

2.  Role of Kupffer cells in the progression of CRC liver metastases after the first stage of ALPPS.

Authors:  Rocio García-Pérez; Joana Ferrer Fábrega; Aranzazu Varona-Bosque; Carlos Manuel Martínez; Beatriz Revilla-Nuin; Laia Cabellos; Romina Pena; Ramón Vilana; Carolina Gonzalez-Abós; Juan Carlos García-Valdecasas; José Fuster Obregón
Journal:  Sci Rep       Date:  2018-05-24       Impact factor: 4.379

3.  Partial ALPPS with a longer wait between procedures is safe and yields adequate future liver remnant hypertrophy.

Authors:  Nagappan Kumar; Trish Duncan; David O'Reilly; Zsolt Káposztás; Craig Parry; John Rees; Sameer Junnarkar
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2019-02-28

4.  Did the International ALPPS Meeting 2015 Have an Impact on Daily Practice? The Hamburg Barmbek Experience of 58 Cases.

Authors:  Gregor A Stavrou; Marcello Donati; Mohammad H Fard-Aghaie; Martin Zeile; Tessa M Huber; Axel Stang; Karl J Oldhafer
Journal:  Visc Med       Date:  2017-11-30

5.  Associated Liver Partition and Portal Vein Ligation (ALPPS) vs Selective Portal Vein Ligation (PVL) for Staged Hepatectomy in a Rat Model. Similar Regenerative Response?

Authors:  Rocío García-Pérez; Beatriz Revilla-Nuin; Carlos M Martínez; Angel Bernabé-García; Alberto Baroja Mazo; Pascual Parrilla Paricio
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.